Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Sarepta Therapeutics Earns Membership In 95-Plus Composite Rating Club

Sarepta Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Monday, from 92 to 99.

The new score means the company is now outperforming 99% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.

Sarepta Therapeutics has now climbed above a proper buy zone after clearing the 146.68 buy point in a consolidation.

Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets

The stock sports an 81 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 81% of all stocks.

Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.

The company posted a 0% rise in earnings for Q1. Sales growth climbed 63%, up from 54% in the prior report. The company has now posted rising growth in each of the last three reports.

Sarepta Therapeutics earns the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the top-ranked stock within the group.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.